NCT05112419View on ClinicalTrials.gov

A Study to Assess Zibotentan Pharmacokinetics in Participants With Moderate Hepatic and Moderate Renal Impairment

PHASE1CompletedINTERVENTIONAL

Enrollment

12

Participants

Timeline

Start Date

November 10, 2021

Primary Completion Date

December 15, 2021

Study Completion Date

December 15, 2021

Conditions

Hepatic ImpairmentRenal Impairment

Interventions

DRUG

Zibotentan

All participants will receive a single oral dose of zibotentan capsule under fasted conditions.

Trial Locations (1)

1612

Research Site, Sofia

Sponsors

Lead Sponsor

All Listed Sponsors

lead

AstraZeneca

INDUSTRY